|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
3xTg-AD mice had an increased pro-inflammatory response characterised by the production of pro-inflammatory mediators such as tumour necrosis TNF-α, IL-6, CCL5 and CXCL-1, as well as an increase in immune cell infiltration to the sites of infection.
|
28284226 |
2017 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour necrosis factor (TNF) signalling molecules are considered as promising therapeutic targets of antirheumatic therapy.
|
15642137 |
2005 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour necrosis factor (TNF) significantly increased fractalkine mRNA (>100 fold) and protein expression, which was associated with increased shedding of fractalkine from the cell.
|
19324423 |
2009 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TNF-α inhibition resulted in suppression of IL-6 and IL-8 in parallel with clinical improvement in all anti-TNF-treated subjects, but was also associated with elevated TNF-α and IL-17 in etanercept-treated subjects.
|
26934060 |
2016 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor necrosis factor-α (TNF-α)-induced protein 8-like-2 (TNFAIP8L2 or TIPE2), a member of the tumor necrosis TNFAIP8 family, was found to be involved in the development and progression of several tumors.
|
28081733 |
2017 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor necrosis factor (TNF) signaling is required for inflammatory nociceptive (pain) sensitization in Drosophila and vertebrates.
|
28492538 |
2017 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour necrosis factor (TNF) signalling is mediated via two receptors, TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2), which work antithetically to balance CNS immune responses involved in autoimmune diseases such as multiple sclerosis.
|
30206422 |
2018 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, the majority of DEGs were mainly enriched in NF-kappa β (NF-kβ) signaling pathway and tumor necrosis factor (TNF) signaling pathway.
|
31277141 |
2019 |
|
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level.
|
22608605 |
2012 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of tumor necrosis factor (TNF) signaling pathway which regulates the transcription factor Nuclear Factor κB (NF-κB) using this method identifies two types of incorrect cell decisions called false alarm and miss.
|
28379950 |
2017 |
|
Tumor necrosis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Analytes of the tumor necrosis factor (TNF) signaling pathway (KEGG ID:4668) in the CSF and plasma best correlated with CSF t-tau and p-tau levels, and analytes of the complement and coagulation pathway (KEGG ID:4610) best correlated with CSF Aβ42 levels.
|
31353852 |
2019 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Autocrine tumor necrosis factor (TNF) signaling in the absence of TAK1 induced spontaneous RIPK1-dependent NLRP3 inflammasome activation and cell death.
|
29500178 |
2018 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Biologic therapy, such as those that target tumor necrosis factor (TNF) signaling, has proven to be an efficacious method of treatment for patients with inflammatory bowel disease (IBD) with regards to symptom management and mucosal healing.
|
28373759 |
2017 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD40, CD80, CD86 and major histocompatibility complex (MHC) class II], as well as the production of cytokines [e.g. interleukin (IL)-1β, IL-12p70 and tumour necrosis gactor (TNF)-α] compared with those of unstimulated controls.
|
21910723 |
2011 |
|
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Chondrocytes from normal joint cartilage were cultured <i>in vitro</i> for interleukin 6 (IL6) or tumor necrosis factor (TNF) treatment and si-NR4A1 transfection, after which the possible mechanism involving NR4A1 was analyzed.
|
28337303 |
2017 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Computational analyses revealed that 28 of the differentially expressed (DE) mRNAs were associated with eight DE lncRNAs involved in chemokine signaling pathways, the nuclear factor-kappa B (NF-κB) signaling pathway, and tumor necrosis factor (TNF) signaling pathway.
|
27188286 |
2016 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Consecutive CD patients with intestinal strictures that initiated treatment with anti-tumor necrosis alpha (anti-TNF) between June 2012 and April 2017 with MRE adjacent to treatment onset were retrospectively collected.
|
29779158 |
2018 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Contribution of the TNF-α (Tumor Necrosis Factor-α)-TNF-Rp55 (Tumor Necrosis Factor Receptor p55) Axis in the Resolution of Venous Thrombus.
|
30354252 |
2018 |
|
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Deletion of key genes within the tumor necrosis factor (TNF) signaling, interferon-γ (IFN-γ) signaling, and antigen presentation pathways provided protection of tumor cells from CD8<sup>+</sup> T cell-mediated killing and blunted antitumor immune responses in vivo.
|
29776993 |
2018 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.
|
15515013 |
2005 |
|
Tumor necrosis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Functional analysis of DEGs obtained that inflammatory responses, immune responses, and positive regulation of apoptosis, tumor necrosis factor (TNF) signaling pathway, and osteoclast differentiation may be involved in the pathogenesis of OA.
|
30317616 |
2019 |
|
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Functional enrichment analyses suggested that the upregulated genes were markedly enriched in inflammation-related biological processes, as well as in the tumor necrosis factor (TNF) signaling pathway, cytokine-cytokine receptor interactions, complement and coagulation cascades, and in the chemokine signaling pathway.
|
31044753 |
2020 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
GO and KEGG analyses revealed roles for the potential mRNA targets of MIR137HG in epithelial cell differentiation and the peroxisome proliferator-activated receptor (PPAR) and tumor necrosis factor (TNF) signaling pathways.
|
31308745 |
2019 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Histopathologic examination of the tumor mass from immunocompetent mice demonstrated centralized hemorrhagic tumor necrosis (38%) after inoculation of the HSV-TK-modified tumor cells and GCV in tumor-bearing mice compared with the control mice (5%), indicating that cytokines such as tumor necrosis factor-alpha (TNF-alpha) were being released locally.
|
8647234 |
1996 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hypersensitivity of autophagy gene-deficient cells to IFNγ was mediated by tumor necrosis factor (TNF) signaling via receptor interacting protein kinase 1 (RIPK1)- and caspase 8-mediated cell death.
|
31346084 |
2019 |